Charles Geyer, MD, FACP

Articles

Trastuzumab Deruxtecan in the Neoadjuvant Setting

February 8th 2023

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.

The Emerging State of HER2-low Breast Cancer

February 1st 2023

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Unmet Needs for Patients with HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Key Takeaways from Clinical Trials of Trastuzumab Deruxtecan in Different Populations

January 25th 2023

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

Recent Updates for the Advanced HR+ Breast Cancer Setting

January 25th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

Clinical Implications of SERENA-2 Trial Data

January 18th 2023

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

Novel Agents in the Adjuvant Setting: PARP Inhibitors

January 18th 2023

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

Updates in the Treatment of Early-stage HR+ Breast Cancer

January 11th 2023

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

The Evolution of the Breast Cancer Treatment Landscape

January 11th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

March 2nd 2022

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

March 2nd 2022

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

February 23rd 2022

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

February 23rd 2022

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

February 16th 2022

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

February 16th 2022

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

February 9th 2022

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

February 9th 2022

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

Monitoring Patients With HER2+ Metastatic Breast Cancer

February 2nd 2022

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Patient Case: Frontline Treatment Options for HER2+ mBC

February 2nd 2022

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.